Avastin delays progression of ovarian cancer

CHICAGO (Reuters) – Adding cancer drug Avastin to standard chemotherapy doubled the length of time a certain group of advanced ovarian cancer patients lived without their disease getting worse, according to results of a clinical trial. The study involved 361 women whose cancer had stopped responding to traditional platinum-based chemotherapy. After a median follow-up of 13.5 months, 75 percent of Avastin patients had a recurrence of cancer, compared to 91 percent of those who received chemotherapy alone. The median time to disease progression or death was 6. …